Maze Therapeutics, Inc. Common Stock (MAZE) — Financial Flexibility Index

Latest as of December 2025: -0.66x

Maze Therapeutics, Inc. Common Stock (MAZE) has a Financial Flexibility Index of -0.66x as of December 2025. Free cash flow of $-27.70 Million (operating CF $-27.73 Million minus capex $34.00K) represents -1% of total liabilities ($42.16 Million). Also explore how fast is Maze Therapeutics, Inc. Common Stock growing its equity to track the company's year-over-year net asset growth rate.

Financial Flexibility Index

-0.66x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-27.70 Million
Operating CF − Capex

Total Liabilities

$42.16 Million
USD

Capital Expenditures

$34.00K
USD

Maze Therapeutics, Inc. Common Stock Financial Flexibility Index (2022–2025)

Historical Financial Flexibility Index trend for Maze Therapeutics, Inc. Common Stock across 4 annual periods. Check Maze Therapeutics, Inc. Common Stock PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Annual Financial Flexibility Index for Maze Therapeutics, Inc. Common Stock (2022–2025)

Year-by-year free cash flow to debt coverage for Maze Therapeutics, Inc. Common Stock. For the full company profile including market capitalisation, see Maze Therapeutics, Inc. Common Stock stock valuation.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -2.64x $-111.15 Million $-111.94 Million $42.16 Million ▼ -249.2%
2024 1.77x $77.10 Million $75.95 Million $43.64 Million ▲ +225.7%
2023 -1.41x $-86.39 Million $-86.83 Million $61.45 Million ▲ +29.9%
2022 -2.00x $-97.24 Million $-99.20 Million $48.51 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities